Keyword Analysis & Research: clinicaltrials.gov pfizer
Keyword Research: People who searched clinicaltrials.gov pfizer also searched
Search Results related to clinicaltrials.gov pfizer on Search Engine
-
A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and
https://classic.clinicaltrials.gov:443/ct2/show/NCT04816643
WEBMar 25, 2021 · ClinicalTrials.gov Identifier: NCT04816643. Recruitment Status : Completed. First Posted : March 25, 2021. Last Update Posted : December 19, 2023. …
DA: 79 PA: 31 MOZ Rank: 91
-
MagnetisMM-5: Study of Elranatamab (PF-06863135) …
https://classic.clinicaltrials.gov:443/ct2/show/NCT05020236
WEBAug 25, 2021 · ClinicalTrials.gov Identifier: NCT05020236. Recruitment Status : Recruiting. First Posted : August 25, 2021. Last Update Posted : March 12, 2024. See … Allocation: Randomized Intervention Model: Factorial Assignment Estimated Enrollment : 762 participants Study Type : Interventional (Clinical Trial)
Allocation: Randomized
Intervention Model: Factorial Assignment
Estimated Enrollment : 762 participants
Study Type : Interventional (Clinical Trial)
DA: 76 PA: 31 MOZ Rank: 9
-
Pfizer-BioNTech COVID-19 Vaccine Effectiveness Study
https://classic.clinicaltrials.gov:443/ct2/show/NCT04848584
WEBApr 19, 2021 · ClinicalTrials.gov Identifier: NCT04848584. Recruitment Status : Recruiting. First Posted : April 19, 2021. Last Update Posted : February 6, 2024. See Contacts and …
DA: 47 PA: 73 MOZ Rank: 33
-
To Evaluate the Safety, Tolerability, and Immunogenicity of …
https://classic.clinicaltrials.gov:443/ct2/show/NCT04754594
WEBClinicalTrials.gov Identifier: NCT04754594. Recruitment Status : Completed. First Posted : February 15, 2021. Last Update Posted : July 13, 2023. View this study on the … Actual Enrollment : 683 participants Intervention Model: Parallel Assignment Allocation: Randomized Study Type : Interventional (Clinical Trial)
Actual Enrollment : 683 participants
Intervention Model: Parallel Assignment
Allocation: Randomized
Study Type : Interventional (Clinical Trial)
DA: 36 PA: 1 MOZ Rank: 68
-
Safety and Efficacy of a Third Dose of BNT162b2 …
https://www.nejm.org:443/doi/full/10.1056/NEJMoa2200674
WEBMar 23, 2022 · In an ongoing pivotal clinical trial (C4591001) involving healthy children and adults who were 12 years of age or older, two doses of the BNT162b2 vaccine (30 μg) were safe, immunogenic, and at...
DA: 6 PA: 96 MOZ Rank: 12
-
Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 …
https://www.pfizer.com:443/news/press-release/press-release-detail/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine
WEBNov 18, 2020 · A breakdown of the diversity of clinical trial participants can be found here from approximately 150 clinical trials sites in United States, Germany, Turkey, South …
DA: 86 PA: 9 MOZ Rank: 21
-
Safety and Efficacy of the BNT162b2 mRNA Covid-19 …
https://www.nejm.org:443/doi/full/10.1056/NEJMoa2034577
WEBDec 10, 2020 · (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728 .) Quick Take. Safety and Efficacy of the BNT162b2 Covid-19 Vaccine. 3m 0s.
DA: 65 PA: 21 MOZ Rank: 93
-
Pfizer Announces Additional Phase 2/3 Study Results Confirming …
https://www.pfizer.com:443/news/press-release/press-release-detail/pfizer-announces-additional-phase-23-study-results
WEBFor more information on the EPIC Phase 2/3 clinical trials for PAXLOVID, visit clinicaltrials.gov. About Pfizer: Breakthroughs That Change Patients’ Lives. At Pfizer, …
DA: 52 PA: 58 MOZ Rank: 74
-
Safety, Immunogenicity, and Efficacy of the BNT162b2 …
https://www.nejm.org:443/doi/full/10.1056/NEJMoa2107456
WEBPublished May 27, 2021. N Engl J Med 2021;385: 239 - 250. DOI: 10.1056/NEJMoa2107456. VOL. 385 NO. 3. Abstract. Background. Until very recently, vaccines against severe acute respiratory syndrome...
DA: 14 PA: 92 MOZ Rank: 88
-
Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate …
https://www.pfizer.com:443/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidate
WEBNov 5, 2021 · 2024. Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR …
DA: 41 PA: 89 MOZ Rank: 32